MedTrace Logo

A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico

NCT07494058 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2026-03-27

No results posted yet for this study

Summary

During the COVID-19 pandemic, home treatment for conditions such as Fabry, Gaucher or Hunter became important because it is easier for people to stick to their treatment if medicines that need to be given as infusion (called intravenous or IV treatment) can be given at home or somewhere close to home. Additionally, many of the hospitals that provide infusions are centralized in Mexico.

The main aim of the study is to find out whether people with Fabry, Gaucher or Hunter condition are more likely to continue and follow their treatment properly (called 'treatment adherence') when they receive it at home compared to when they receive it at a hospital. Other aims are to understand the factors that can influence treatment adherence, to learn about any regional differences in Mexico and to understand any medical problems with either treatment (home or hospital).

No treatment will be given during this study. Only already existing data will be reviewed during this study.

Conditions

  • Lysosomal Disease

Interventions

OTHER

No intervention

This is a non-interventional study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-11
Primary Completion
2026-08-01
Completion
2026-08-01

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07494058 on ClinicalTrials.gov